University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Study to Determine Appropriate Dose of Medication for Patients with diagnosed with Recurring Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Official Title

Study to Determine Appropriate Dose of Medication for Patients with diagnosed with Recurring Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Description

Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Who can apply: People diagnosed with recurring ovarian, primary peritoneal, or fallopian tube cancer.

Purpose: To determine the appropriate dose of an experimental drug, evaluate side effects when combined with other drugs, and test samples of tumor tissue (if available from a previous surgery or biopsy).

Drugs: ABT-888 (Veliparib), carboplatin and pegylated liposomal doxorubicin (PLD).

Number of participants: 10.

Start Date
July 17, 2012
End Date
May 27, 2014
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
David Bender, MD
Contact Info

Sharon Stockman, 319-356-2015

Department
Department or Field of Study
Keywords
cancer ; Carboplatin ; De Geest ; endometrioid adenocarcinoma ; fallopian tube ; IRB#201206747 ; mixed epithelial carcinoma ; NCI Supplied Veliparib (ABT-888) ; ovarian clear cell cystadenocarcinoma ; Pegylated Liposomal Doxorubicin (PLD) ; Phase 1 ; Phase I ; Primary Peritoneal and Fallopian Tube Cancer ; recurrent epithelial cancer ; recurrent primary peritoneal cavity ; serous ; undifferentiated ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.